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 Purpose: To estimate the cost-effectiveness of computed tomographic 
(CT) colonography for colorectal cancer (CRC) screening 
in average-risk asymptomatic subjects in the United States 
aged 50 years .
 Materials and 
Methods: 
Enrollees in the American College of Radiology Imag-
ing Network National CT Colonography Trial provided 
informed consent, and approval was obtained from the 
institutional review board at each site. CT colonography 
performance estimates from the trial were incorporated 
into three Cancer Intervention and Surveillance Model-
ing Network CRC microsimulations. Simulated survival 
and lifetime costs for screening 50-year-old subjects in 
the United States with CT colonography every 5 or 10 
years were compared with those for guideline-concordant 
screening with colonoscopy, fl exible sigmoidoscopy plus 
either sensitive unrehydrated fecal occult blood testing 
(FOBT) or fecal immunochemical testing (FIT), and no 
screening. Perfect and reduced screening adherence sce-
narios were considered. Incremental cost-effectiveness and 
net health benefi ts were estimated from the U.S. health 
care sector perspective, assuming a 3% discount rate.
 Results: CT colonography at 5- and 10-year screening intervals was 
more costly and less effective than FOBT plus fl exible sig-
moidoscopy in all three models in both 100% and 50% 
adherence scenarios. Colonoscopy also was more costly 
and less effective than FOBT plus fl exible sigmoidoscopy, 
except in the CRC-SPIN model assuming 100% adherence 
(incremental cost-effectiveness ratio: $26 300 per life-year 
gained). CT colonography at 5- and 10-year screening in-
tervals and colonoscopy were net benefi cial compared with 
no screening in all model scenarios. The 5-year screening 
interval was net benefi cial over the 10-year interval except 
in the MISCAN model when assuming 100% adherence 
and willingness to pay $50 000 per life-year gained.
 Conclusion: All three models predict CT colonography to be more costly 
and less effective than non-CT colonographic screening 
but net benefi cial compared with no screening given model 
assumptions.
 q RSNA, 2011
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 Materials and Methods 
 We analyzed data from NCTCT to 
obtain per-patient defi nitions of sensitiv-
ity and specifi city that refl ect colonos-
copy referral patterns likely to be en-
countered in practice. Enrollees provided 
informed consent, and approval was 
obtained from the institutional review 
board at each site. Industry support for 
the American College of Radiology Im-
aging Network (ACRIN 6664) trial was 
provided by GE Healthcare (Waukesha, 
Wis) for in-kind use of training facili-
ties, by E-Z-Em (Lake Success, NY) for 
in-kind training and equipment supplied 
at cost, and by Bracco Imaging (Princ-
eton, NJ) for supplying their stool tag-
ging product. The industry supporters 
did not have access to the data reported 
herein. These results were then incor-
porated into the CISNET CRC models 
to estimate the cost-effectiveness and 
net health benefi t of CT colonography 
relative to guideline-concordant screening 
orectal cancer (CRC), including CT col-
onography at 5-year intervals ( 8 ). How-
ever, the U.S. Preventive Services Task 
Force recommends fewer choices and 
excludes CT colonography due to insuf-
fi cient evidence ( 9 ). 
 Because successful CRC screening 
and removal of adenomas can avert 
the development of carcinoma poten-
tially many years in the future, only 
a few controlled trials have been able 
to assess the long-term effectiveness of 
CRC screening ( 10–12 ). Instead, deci-
sion makers have relied on simulations 
of the natural history of colorectal neo-
plasia to extrapolate long-run costs and 
health consequences from test perfor-
mance characteristics ( 13 ). Such mod-
els vary widely in underlying formu-
las and data sources used to estimate 
model parameters. 
 Recognizing both the importance 
and variability of such models, the Na-
tional Cancer Institute sponsored the 
Can cer Intervention and Surveillance 
Modeling Network (CISNET). CISNET 
is a collaborative effort—with indepen-
dent teams using their own unique 
model structures and common sources 
of data to simulate the natural history 
of various cancers. The CISNET CRC 
group includes three validated models: 
MISCAN ( 14,15 ), CRC-SPIN ( 16 ), and 
SimCRC ( 17 ). The purpose of this analysis 
was to estimate the cost-effectiveness 
of CT colonography for CRC screen-
ing in average-risk asymptomatic 
subjects in the United States aged 50 
years. 
 The American College of Radiology Imaging Network enrolled 2600 asymptomatic subjects aged 50 years 
or older into the American College of 
Radiology Imaging Network National CT 
Colonography Trial (NCTCT) ( 1 ). Indi-
viduals were scheduled to undergo com-
puted tomographic (CT) colonography 
followed by colonoscopy, which for trial 
purposes served as the reference stan-
dard. The NCTCT was designed to ad-
dress widely varying results from previ-
ously conducted CT colonography trials 
( 2–7 ). Results of the NCTCT confi rmed 
that CT colonography depicts colorec-
tal adenomas and carcinomas (neopla-
sia) with sensitivities of 78%–90% and 
specifi cities of 86%–88%, depending on 
lesion size. 
 However, it remains unclear whether, 
given these performance characteris-
tics, screening with CT colonography 
is an effi cient use of resources. Joint 
guidelines from the American Cancer 
Society and U.S. Multi-Society Task Force 
on Colorectal Cancer recommend vari-
ous options for screening average-risk 
individuals older than 50 years for col-
 Implication for Patient Care 
 Although predicted to be more  n
costly and less effective than 
other currently recommended 
colorectal cancer screening 
approaches, performing CT colono-
graphy at 5-year intervals is 
likely to be net benefi cial com-
pared with no screening and 
therefore may be a cost-
effective alternative for screen-
ing patients unwilling or unable 
to use other recommended 
modalities. 
 Advances in Knowledge 
 On the basis of an analysis of  n
data from the American College 
of Radiology Imaging Network 
National CT Colonography Trial 
and three Cancer Intervention 
and Surveillance Modeling Net-
work (CISNET) colorectal cancer 
microsimulations, screening an 
asymptomatic, average-risk 
cohort of 50-year-old subjects in 
the United States every 5 or 
10 years with CT colonography is 
predicted to cost more and be 
less effective than guideline-
concordant non-CT colono-
graphic screening approaches. 
 Screening with CT colonography  n
is predicted by all three CISNET 
models to be net benefi cial com-
pared with no screening. 
 Five-year CT colonographic  n
screening intervals are predicted 
to be net benefi cial compared 
with 10-year intervals. 
 Published online before print 
 10.1148/radiol.11102411  Content codes:    
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 Abbreviations: 
 CISNET = Cancer Intervention and Surveillance 
Modeling Network 
 CRC = colorectal cancer 
 FIT = fecal immunochemical testing 
 FOBT = fecal occult blood testing 
 ICER = incremental cost-effectiveness ratio 
 NCTCT = National CT Colonography Trial 
 SEER = Surveillance, Epidemiology, and End Results 
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nology assessment ( 35 ), assuming that 
perforation rates do not differ by oc-
currence of biopsy as suggested by a 
recent outpatient study ( Table 1 ) ( 39 ). 
We assumed a CT colonography perfo-
ration rate of two per 21 923 ( 36 ). Some 
evidence suggests that perforations 
associated with CT colonography may 
be less harmful than those associated 
with colonoscopy ( 37,38 ); however, to 
be conservative, we assumed that per-
forations associated with CT colonogra-
phy had the same 5.2% mortality rate 
( 41 ) and cost as those associated with 
colonoscopy. 
 Costs 
 We used 2007 Medicare fee schedules 
and reimbursement formulas to proxy 
direct medical costs of procedures and 
complications ( 40 ), using site-of-care 
weights derived from Center for Medi-
care and Medicaid Services data when 
available ( Table 1 ) ( 35 ). We adjusted 
colonoscopy costs to account for the es-
timated need to repeat 5% of outpatient 
colonoscopies due to inadequate bowel 
preparation, diffi cult patient anatomy, 
and/or operator error ( 43 ). 
 The Center for Medicare and Med-
icaid Services has not assigned relative 
value units for screening CT colonogra-
phy. To maintain comparability of cost-
ing methods, we combined Medicare 
reimbursement–based cost estimates for 
CT of the abdomen without contrast 
material (CPT-74150), CT of the pelvis 
without contrast material (CPT-72192), 
and three-dimensional image reconstruc-
tion with postprocessing (CPT-76377) 
and applied a cost-reduction factor to 
account for resource savings associated 
with imaging contiguous anatomic re-
gions ( 44 ). 
 We estimated complication costs 
from Medicare average reimbursement 
for diagnosis-related groups and pro-
cedures representative of each com-
plication type ( Table 1 ) ( 35 ). Annual 
cancer treatment costs were based on 
a retrospective analysis of SEER data 
linked to 1999–2003 Medicare claims, 
comparing costs of patients with CRC 
by stage and phase of care to sex, age, 
and geography-matched control sub-
jects ( 35,42 ). 
 Sensitivity of CT colonography was 
derived on a per-patient basis to refl ect 
the clinical practice of referral of a pa-
tient with any suspicious lesion measur-
ing at least 5 mm at CT colonography 
to follow-up colonoscopy. The operating 
characteristics of CT colonography are 
likely to vary when patients have larger 
or multiple adenomas. Therefore, we 
analyzed NCTCT data to estimate the 
probability that any suspicious lesion 
measuring at least 5 mm would be re-
ported for a patient given the number 
of pathologically confi rmed adenomas 
or carcinomas (none, one, two, or three 
or more) and the size of the largest 
lesion (1–5 mm, 6–9 mm,   10 mm), 
assuming all carcinomas were at least 
10 mm ( Table 1 ) . We defi ned specifi city 
to be the probability that CT colonogra-
phy did not depict any suspicious lesions 
measuring at least 5 mm, given that 
an individual had no pathologically con-
fi rmed neoplasia of any size ( Table 1 ). 
 The test performance characteristics 
of modalities other than CT colonog-
raphy were adapted from a recent tech-
nology assessment commissioned by the 
Center for Medicare and Medicaid Ser-
vices ( 35 ) ( Table 1 ). Because colonos-
copy and sigmoidoscopy depict individ-
ual lesions and stool tests help detect 
the gross presence of blood, we applied 
colonoscopy and sigmoidoscopy sensi-
tivity on a per-lesion basis and stool test 
sensitivity conditional on the number 
and size of adenomas ( Table 1 ). Dur-
ing years in which both sigmoidoscopy 
and stool testing are scheduled, we as-
sumed that the stool test occurred fi rst, 
and, if positive, triggered direct referral 
to colonoscopy. Detection and removal 
of hyperplastic polyps are not modeled 
explicitly but instead are refl ected in 
the specifi city estimates of each test. 
 In our base case, we assumed 100% 
adherence to all recommended screening, 
follow-up, and surveillance to com pare 
cost-effectiveness of the approaches for 
subjects who adhered to the guidelines. 
We also conducted a sensitivity analysis 
scenario with 50% adherence to screen-
ing tests and 100% adherence to diag-
nostic and surveillance colonoscopy. 
 We adapted endoscopic complica-
tion rates from the aforementioned tech-
strategies and no screening for the 
average-risk population aged 50 years 
and older, from a U.S. health care sector 
perspective. 
 Natural History Models 
 Each model simulates large cohorts rep-
resentative of 50-year-old subjects in the 
United States in 2007. In all models, each 
simulated individual may develop ad-
enomas beginning at age 20 years in one 
of six locations:  (a) cecum,  (b) ascending 
colon,  (c) transverse colon,  (d) descend-
ing colon,  (e) sigmoid colon, and  (f) rec-
tum. Adenoma risk depends on age, sex, 
and individual risk factors. Multiple ade-
nomas may arise over a lifetime. A subset 
of adenomas may grow and/or become 
carcinomas. Undiagnosed carcinomas 
may progress from stage I to stage IV or 
be detected clinically, with survival as-
signed according to stage at detection on 
the basis of Surveillance, Epidemiology, 
and End Results (SEER) data from 1996 
to 1999 ( 18 ). Non-CRC-related death 
rates came from U.S. life tables ( 19 ). 
 There are few longitudinal studies 
of the adenoma-carcinoma sequence 
( 20–22 ); hence, many natural history 
parameters are unknown. The CISNET 
models use a common set of calibration 
data on adenoma prevalence by age 
( 23–32 ) and prescreening CRC incidence 
by age, stage, and location from SEER 
(1975–1979) ( 18 ). CISNET maintains 
standardized, detailed technical profi les 
of each model on the Internet ( 33 ). 
 Screening Models 
 In each simulation, natural history can be 
interrupted by detection and removal of 
adenomas or early detection and treat-
ment of carcinomas. We modeled three 
recommended strategies: fl exible sig-
moidoscopy every 5 years plus sensitive 
unrehydrated fecal occult blood testing 
(FOBT) or fecal immunochemical test-
ing (FIT) annually; colonoscopy every 
10 years; and CT colonography every 5 
or 10 years, where all individuals with 
suspicious lesions at least 5 mm undergo 
follow-up colonoscopy. Screening was 
simulated to begin at age 50 years and 
discontinue after age 80 years. Postpo-
lypectomy surveillance followed guide-
lines ( 34 ) and continued until death. 
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 Table 1 
 Screening Model Parameters 
Variable Value Reference(s)
Performance of CT colonography* 1
 Specifi city to adenoma/carcinoma (per patient) 0.909
 Sensitivity to adenoma/carcinoma (per patient) when † 
  Largest adenoma is 1–5 mm 0.172–0.545 
  Largest adenoma is 6–9 mm 0.615–0.667
  Largest adenoma is   10 mm or patient has carcinoma ‡ 0.805–0.947
Performance of unrehydrated FOBT 35
 Specifi city to adenoma/carcinoma (per patient) 0.950
 Sensitivity to adenoma/carcinoma (per patient) when † 
  Largest adenoma is 1–5 mm 0.050
  Largest adenoma is 6–9 mm 0.097–0.111
  Largest adenoma is   10 mm 0.204–0.241
  Patient has any carcinoma 0.700
Performance of FIT 35
 Specifi city to adenoma/carcinoma (per patient) 0.925
 Sensitivity to adenoma/carcinoma (per patient) when † 
  Largest adenoma is 1–5 mm 0.075 
  Largest adenoma is 6–9 mm 0.120–0.134
  Largest adenoma is   10 mm 0.222–0.257
  Patient has any carcinoma 0.700
Performance of fl exible sigmoidoscopy 35
 Specifi city to adenoma/carcinoma (per patient) 0.920
 Sensitivity to adenoma/carcinoma (per lesion) when
  Adenoma or carcinoma is 1–5 mm 0.750 
  Adenoma or carcinoma is 6–9 mm 0.850
  Adenoma or carcinoma is   10 mm 0.950
 Probability segment is reached § 
  Rectum 1.000
  Sigmoid colon 0.800
  Descending colon 0.400 
  Transverse colon 0.000
  Ascending colon 0.000
Performance of colonoscopy 35
 Specifi city to adenoma/carcinoma (per patient) 0.900
 Sensitivity to adenoma/carcinoma (per lesion) when
  Adenoma or carcinoma is 1–5 mm 0.750 
  Adenoma or carcinoma is 6–9 mm 0.850
  Adenoma or carcinoma is   10 mm 0.950
 Probability segment is reached § 
  Rectum 1.000
  Sigmoid colon 0.995
  Descending colon 0.990 
  Transverse colon 0.985
  Ascending colon 0.980
Complications
 Bleeding or serosal burns
  CT colonography (per 100 000) 0.00 36–38
  Colonoscopy (per 100 000) 180.00 35, 39
  Flexible sigmoidoscopy (per 100 000) 0.00 35, 39
  Cost || $2405.57 41
Table1 (continued)
 Following U.S. guidelines, we ap-
plied a 3% annual discount rate to both 
costs and health outcomes unless oth-
erwise noted ( 45 ). Discounting reduces 
the value of future costs and life-years 
gained to refl ect social time prefer-
ences. However, in the case of screen-
ing, where time horizons are long and 
survival benefi ts accrue far into the fu-
ture, it is also useful to consider undis-
counted life-years gained. 
 Economic Evaluation 
 A screening strategy was “dominated” 
if it was more costly and less effective 
than another strategy or “weakly domi-
nated” if dominated by a weighted av-
erage of two strategies. We calculated 
the incremental cost-effectiveness ratio 
(ICER) for each nondominated strat-
egy as the ratio of the incremental cost 
( D C) to incremental years of life gained 
( D YLG) compared with the next-least-
costly, nondominated strategy (ICER = 
 D C/ D YLG). 
 Frontier plots ( 46 ) for each model 
and adherence scenario were con-
structed showing the total discounted 
life-years gained versus additional costs 
for each screening strategy relative to no 
screening. The origin ($0, 0 life-years 
gained) corresponds to “no screening” 
as the baseline comparator. Moving 
from left to right represents increasing 
cost, whereas moving from bottom to 
top represents improving outcomes. For 
each model, the outer envelope (upward 
and to the left) comprises screening 
strategies that have the potential to be 
cost-effective, depending on willingness 
to pay per life-year gained. Points be-
low and to the right of the envelope are 
either dominated or weakly dominated. 
The ICERs for nondominated screen-
ing strategies can be visualized as the 
inverse of the slopes of segments con-
necting the outer envelope of strategies. 
 We also calculated the net health 
benefi t of each strategy with the following 
formula: life-years gained  2 (cost/ l ), 
where  l is one of three “opportunity 
costs” ($50,000, $75,000, or $100,000) 
per life-year gained ( 47 ). The opportu-
nity cost  l refl ects the cost necessary 
to save 1 year of life if resources spent 
on CRC screening instead were spent 
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and FOBT plus fl exible sigmoidoscopy 
increased life expectancy and reduced 
lifetime CRC risk more than CT colono-
graphic screening at 5- or 10-year in-
tervals. When screening adherence was 
50%, performing CT colonography every 
5 years reduced CRC risk more than 
colonoscopy in two of the three models 
(MISCAN: 39.1% vs 38.7%; SimCRC: 
61.6% vs 59.5%) and had higher un-
discounted life-years gained than did 
colonoscopy in all models ( Table 2 ). 
 Predicted cost and effectiveness 
were similar across the models ( Table 3 ). 
With 100% adherence, all models pre-
dicted total costs to be lowest with 
no screening ($1982–$2459) and high-
est with CT colonography every 5 years 
($2900–$3854). With 50% screening ad-
herence, all models found CT colonog-
raphy every 5 years to be the most 
costly ( Table 3 ). Two models found that 
screening with conventional methods re-
duced total costs relative to no screen-
ing (CRC-SPIN: $1978 for FOBT plus 
fl exible sigmoidoscopy vs $1982 for no 
screening; SimCRC: $2188 for FOBT 
plus fl exible sigmoidoscopy, $2239 for 
FIT plus fl exible sigmoidoscopy, and 
$2447 for colonoscopy vs $2459 for no 
screening) ( Table 3 ). 
 We represent cost-effectiveness us-
ing a frontier graph ( Figure ), with each 
point representing the incremental cost 
and incremental effectiveness of a strat-
egy relative to no screening. All models 
place FOBT plus fl exible sigmoidos-
copy on the cost-effectiveness frontier, 
meaning that FOBT plus fl exible sig-
moidoscopy is cost-effective at some 
willingness-to-pay per life-year gained. 
With 100% adherence, the ICER for 
FOBT plus fl exible sigmoidoscopy com-
pared with no screening ranged from 
dominant (less costly and more effec-
tive) to $12 000 per life-year gained 
( Figure ). None of the models found FIT 
plus fl exible sigmoidoscopy to be cost-
effective relative to FOBT plus fl exible 
sigmoidoscopy at less than $100 000 
per life-year gained; CRC-SPIN, how-
ever, found an ICER of $26 300 per 
life-year gained for colonoscopy rela-
tive to FOBT plus fl exible sigmoidos-
copy; colonoscopy was dominated in 




  CT colonography (per 100 000) 4.56 36–38
  Colonoscopy (per 100 000) 70.00 35, 39
  Flexible sigmoidoscopy (per 100 000) 2.00 35, 39
  Cost || $14 695.67 40
 Death
  CT colonography (per 100 000) 0.24 36–38, 41
  Colonoscopy (per 100 000) 3.63 35, 39, 41
  Flexible sigmoidoscopy (per 100 000) 0.00 35, 39, 41
  Cost || $0.00 ** 
Screening test costs || 36, 40
 Unrehydrated FOBT $4.54
 FIT $22.22
 Flexible sigmoidoscopy $214.78
 Colonoscopy without polypectomy § $724.74
 Colonoscopy with polypectomy and pathology § $867.71
 CT colonography $514.41
Cancer-related annual costs || 35, 42
 Stage I at detection
  Year of diagnosis $29 558
  Continuing years $2504
  Last year of life (death from CRC) $53 546
  Last year of life (death from other causes) $13 097
 Stage II at detection
  Year of diagnosis $40 932
  Continuing years $2334
  Last year of life (death from CRC) $53 316
  Last year of life (death from other causes) $11 378
 Stage III at detection
  Year of diagnosis $50 470
  Continuing years $3372
  Last year of life (death from CRC) $56 475
  Last year of life (death from other causes) $15 164
 Stage IV at detection
  Year of diagnosis $66 811
  Continuing years $10 785
  Last year of life (death from CRC) $75 803
  Last year of life (death from other causes) $40 910
* Ranges refl ect the presence of multiple lesions.
 † Reanalyzed trial data (see text).
 ‡ Carcinomas are assumed to be at least 10 mm.
 § Assuming a repeat procedure for incomplete colonoscopy.
 || In 2007 U.S. dollars
** All deaths incur costs of perforation.
 Screening Model Parameters 
elsewhere in the health sector. A ratio-
nal health care payer should be unwilling 
to pay more than the opportunity cost to 
gain a year of life by means of CRC screen-
ing. Use of the net health benefi t allows 
multiple competing strategies to be rank 
ordered according to economic effi ciency. 
 Results 
 The models project similar lifetime CRC 
risk and life expectancy without screen-
ing ( Table 2 ). If we assume 100% ad-
herence, all models found that colonos-
copy, FIT plus fl exible sigmoidoscopy, 
492 radiology.rsna.org n Radiology: Volume 261: Number 2—November 2011
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 Table 3 
 Incremental Cost-effectiveness Analysis 
Model




Discounted Cost † 
Average Total 
Discounted 




Discounted Cost † 
Average Total 
Discounted 
Years of Life ICER ‡ 
CRC-SPIN No screening $1982 19.301 ... FOBT+FS $1978 19.402 ...
CRC-SPIN FOBT+FS $2316 19.414 $3000 No screening $1982 19.301 Dominated
CRC-SPIN CTC10 $2323 19.398 Dominated COLO $2005 19.380 Dominated
CRC-SPIN COLO $2405 19.418 $26 300 FIT+FS $2016 19.400 Dominated
CRC-SPIN FIT+FS $2421 19.414 Dominated CTC10 $2046 19.362 Dominated
CRC-SPIN CTC5 $2900 19.409 Dominated CTC5 $2255 19.382 Dominated
MISCAN No screening $2180 18.637 ... No screening $2180 18.637 ...
MISCAN CTC10 $3299 18.711 Weakly 
 dominated
COLO $2759 18.697 Weakly 
 dominated
MISCAN FOBT+FS $3324 18.733 $12 000 CTC10 $2765 18.682 Dominated
MISCAN COLO $3358 18.729 Dominated FOBT+FS $2868 18.722 $8200
MISCAN FIT+FS $3404 18.733 Dominated FIT+FS $2892 18.721 Dominated
MISCAN CTC5 $3854 18.725 Dominated CTC5 $3095 18.700 Dominated
SimCRC No screening $2459 19.224 ... FOBT+FS $2188 19.341 ...
SimCRC FOBT+FS $2565 19.362 $800 FIT+FS $2239 19.340 Dominated
SimCRC FIT+FS $2664 19.362 Dominated COLO $2447 19.310 Dominated
SimCRC CTC10 $2708 19.339 Dominated No screening $2459 19.224 Dominated
SimCRC COLO $2743 19.361 Dominated CTC10 $2500 19.291 Dominated
SimCRC CTC5 $3221 19.353 Dominated CTC5 $2667 19.315 Dominated
* Strategies are sorted according to total discounted cost, from lowest to highest. COLO = colonoscopy at 10-year intervals, CTC5 = CT colonography with 5-mm referral threshold at 5-year intervals, 
CTC10 = CT colonography with 5-mm referral threshold at 10-year intervals, FIT+FS = annual FIT plus fl exible sigmoidoscopy at 5-year intervals, FOBT+FS = annual unrehydrated FOBT plus fl exible 
sigmoidoscopy at 5-year intervals.
 † In 2007 U.S. dollars.
 ‡ A strategy is “dominated” if it is more costly and generates fewer total discounted life-years than another strategy; a strategy is “weakly dominated” if it is dominated by a linear combination of two 
other strategies. Incremental cost-effectiveness is compared to the next-least-costly nondominated strategy and is expressed in discounted dollars per discounted life-years gained and rounded to 
the nearest $100.
screen ing adherence, FOBT plus fl ex-
ible sigmoidoscopy dominated all other 
strategies (including no screening) in 
CRC-SPIN and SimCRC and had an 
ICER of $8200 per life-year gained 
compared with no screening in MISCAN 
( Figure ). CT colonography at both 5- 
and 10-year intervals was dominated 
by FOBT plus fl exible sigmoidoscopy 
with either 50% or 100% screening ad-
herence ( Figure ). 
 The models generated similar rank 
ordering of strategies by net health ben-
efi t ( Table 4 ). All screening strategies, 
including CT colonography, were more 
economically effi cient than no screen-
ing in all models at all three opportu-
nity costs and with either 50% or 100% 
screening adherence ( Table 4 ). How-
ever, FOBT plus fl exible sigmoidoscopy, 
FIT plus fl exible sigmoidoscopy, and 
colonoscopy were generally more eco-
nomically effi cient than CT colonogra-
phy at 5- or 10-year intervals, except 
that with 50% screening adherence, 
SimCRC found CT colonography every 
5 years to be more economically effi -
cient than colonoscopy at all three op-
portunity costs ( Table 4 ). The models 
found CT colonoscopy every 5 years 
to be consistently more economically 
effi cient than CT colonography every 
10 years, except under 100% adher-
ence and a $50 000 per life-year gained 
opportunity cost, when CRC-SPIN fa-
vored CT colonography every 10 years 
( Table 4 ). 
 We performed threshold analyses 
in all models and scenarios to account 
for uncertainty about the cost of CT 
colonography. CT colonography would 
have to cost less than $191 for at least 
one model (MISCAN) to predict that 
CT colonography every 5 years would 
be the most net beneficial screening 
strategy in the most favorable circum-
stances ($50 000 per life-year gained 
opportunity cost and 100% adherence). 
The cost of CT colonography would 
have to exceed $1845 for CT colonog-
raphy every 5 years to be less net ben-
efi cial than no screening in at least 
one model (MISCAN) in the least fa-
vorable circumstances ($50 000 per life-
year gained opportunity cost and 50% 
screening adherence). 
 Discussion 
 Our analysis of data from the American 
College of Radiology Imaging Network 
NCTCT in three CISNET microsimula-
tion models predicts CT colonography 
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previous studies by allowing investiga-
tion of convergent validity—the extent 
to which results are sensitive to model 
specifi cation ( 53 ). Although all three 
CISNET models incorporate heteroge-
neous adenoma growth rates, only MIS-
CAN explicitly separates adenomas into 
progressive and nonprogressive types. 
MISCAN consequently offers a shorter 
window of opportunity with which to 
detect progressive adenomas, which ex-
plains why MISCAN showed the lowest 
screening effectiveness. Despite dif-
ferences in absolute effectiveness, the 
high concordance of incremental cost-
effectiveness and rankings by net health 
benefi t was reassuring. 
 There are several limitations to our 
study. We did not specifi cally account 
for extracolonic fi ndings ( 54,55 ) or pos-
sible radiation-related cancer risk ( 56 ) 
stud ies that found CT colonography 
performed at 5- or 10-year intervals 
beginning at age 50 years to be cost-
effective compared with no screening 
($4400–$28 700 per life-year gained) but 
not incrementally cost-effective com-
pared with colonoscopy ( 48–51 ). Our 
results are also consistent with fi nd-
ings from a systematic review of cost-
effectiveness analyses for the U.S. Pre-
ventive Services Task Force that three 
of the four reviewed models that in-
cluded both FOBT plus fl exible sig-
moidoscopy and colonoscopy found 
FOBT plus fl exible sigmoidoscopy to 
gain the most years of life ( 52 ), al-
though we note that one of the three 
models reviewed was a predecessor to 
SimCRC. 
 Our multimodel approach offers 
an advantage over approaches used in 
to be more costly and less effective than 
non-CT colonographic screening but 
net benefi cial compared with no screen-
ing. Although absolute costs and out-
comes differed slightly, the models were 
largely consistent in the relative costs, 
outcomes, and ranking by net benefi ts 
among the strategies. All models found 
that CT colonography at either 5- or 
10-year intervals is likely to be cost-
effective relative to no screening but 
that both strategies were dominated 
by conventional screening tests. The 
models also found colonoscopy likely to 
be more costly and less effective than 
FOBT plus fl exible sigmoidoscopy (except 
with perfect adherence in one model), 
yet colonoscopy is likely to be net benefi -
cial compared with no screening. 
 Our results confi rm those of pre-
viously published Markov modeling 
 
  
 Frontier analysis of cost-effectiveness. For each model, a frontier line connects the outer envelope of screening strategies. Strategies lying below and to the right of 
the frontier are either dominated (both more costly and less effective than a specifi c alternative strategy) or extended-dominated (both more costly and less effective 
than a linear combination of two strategies). Strategies on the frontier represent an effi cient use of resources for some willingness to pay per life-year gained.  COLO = 
colonoscopy at 10-year intervals,  CTC5 = CT colonography with 5-mm referral threshold at 5-year intervals,  CTC10 = CT colonography with 5-mm referral threshold 
at 10-year intervals,  FIT+FS = annual FIT plus fl exible sigmoidoscopy at 5-year intervals,  FOBT+FS = annual unrehydrated FOBT plus fl exible sigmoidoscopy at 
5-year intervals. 
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care data to estimate costs of treating 
CRC, higher costs associated with novel 
chemotherapeutics and biologics may 
not be fully refl ected ( 59,60 ). Under-
estimating CRC costs potentially bi ases 
cost-effectiveness against strategies most 
effective at preventing cancer because 
the potential cost savings of avoiding can-
cer treatment are reduced. 
 Like the above-referenced cost-
effectiveness analyses of CT colonogra-
phy, we did not address quality of life. 
If early detection of neoplasia increases 
quality as well as quantity of life, this 
exclusion may bias against screening. 
However, anxiety, discomfort, and activ-
ity limitation associated with screening 
itself may have a direct impact on qual-
ity of life. The direction and persistence 
of such impacts is unclear ( 61–64 ). 
 Our scenarios assume equal ad-
herence with each screening test. If 
effectiveness in Health and Medicine 
guidelines ( 45 ). However, our fi ndings 
are comparable with those of other stud-
ies of CT colonography cost-effectiveness, 
which also are not reference cases. 
 Because the Center for Medicare 
and Medicaid Services has not estab-
lished relative value units for screening 
CT colonography reimbursement, we 
constructed a proxy by combining CT 
procedures, following an approach used 
in other analyses ( 51,58 ). Our threshold 
analysis suggests that CT colonography 
costs can vary over a wide range (from 
half to three times the estimated cost) 
before altering the fundamental result 
that all three models agree CT colonog-
raphy screening is economically effi cient 
compared with no screening but not cost-
effective compared with other methods. 
 Although we used the most recently 
published analysis of SEER-linked Medi-
owing to CT colonography. There are 
limited data to inform the magnitude of 
the benefi ts and harms associated with 
the diagnostic work-up of extracolonic 
fi ndings and the long-term radiation-
related cancer risk. 
 With current CT colonography guide-
lines, colonoscopy referral is recom-
mended only for suspicious lesions mea-
suring at least 6 mm ( 57 ). Our analysis 
used a 5-mm referral threshold; how-
ever, changing this threshold to 6 mm 
in our models resulted in consistent but 
very small reductions in both costs and 
discounted years of life (ranging from 
$3 to $42 and 0.002 to 0.005 years of 
life, respectively, depending on model, 
scenario, and repeat interval). 
 Because we did not include pa-
tient and other sector costs or quality 
of life, our analysis is not a “reference 
case” as defi ned by U.S. Panel on Cost-
 Table 4 
 Net Health Benefi ts 
Model and Screening 
Strategy * 
100% Adherence Scenario 50% Adherence Scenario
$100 000 per Year 
of Life Gained
$75 000 per Year 
of Life Gained
$50 000 per Year 
of Life Gained
$100 000 per Year 
of Life Gained
$75 000 per Year 
of Life Gained
$50 000 per Year 
of Life Gained
CRC-SPIN
 FOBT+FS 19.391 (2) 19.384 (2) 19.368 (2) 19.382 (1) 19.376 (1) 19.363 (1)
 FIT+FS 19.390 (3) 19.382 (3) 19.365 (3) 19.380 (2) 19.373 (2) 19.360 (2)
 COLO 19.394 (1) 19.386 (1) 19.370 (1) 19.360 (3) 19.353 (3) 19.340 (3)
 CTC5 19.380 (4) 19.370 (4) 19.351 (5) 19.360 (4) 19.352 (4) 19.337 (4)
 CTC10 19.375 (5) 19.367 (5) 19.351 (4) 19.341 (5) 19.335 (5) 19.321 (5)
 No screening 19.282 (6) 19.275 (6) 19.262 (6) 19.282 (6) 19.275 (6) 19.262 (6)
MISCAN
 FOBT+FS 18.699 (1) 18.688 (1) 18.666 (1) 18.693 (1) 18.683 (1) 18.664 (1)
 FIT+FS 18.699 (2) 18.688 (2) 18.665 (2) 18.692 (2) 18.682 (2) 18.663 (2)
 COLO 18.696 (3) 18.685 (3) 18.662 (3) 18.669 (3) 18.660 (3) 18.641 (3)
 CTC5 18.686 (4) 18.673 (4) 18.647 (4) 18.669 (4) 18.658 (4) 18.638 (4)
 CTC10 18.678 (5) 18.667 (5) 18.645 (5) 18.655 (5) 18.645 (5) 18.627 (5)
 No screening 18.616 (6) 18.608 (6) 18.594 (6) 18.616 (6) 18.608 (6) 18.594 (6)
SimCRC
 FOBT+FS 19.336 (1) 19.327 (1) 19.310 (1) 19.319 (1) 19.312 (1) 19.297 (1)
 FIT+FS 19.335 (2) 19.326 (2) 19.309 (2) 19.318 (2) 19.310 (2) 19.295 (2)
 COLO 19.333 (3) 19.324 (3) 19.306 (3) 19.286 (4) 19.277 (4) 19.261 (4)
 CTC5 19.321 (4) 19.311 (4) 19.289 (4) 19.288 (3) 19.279 (3) 19.262 (3)
 CTC10 19.312 (5) 19.303 (5) 19.285 (5) 19.266 (5) 19.258 (5) 19.241 (5)
 No screening 19.200 (6) 19.192 (6) 19.175 (6) 19.200 (6) 19.192 (6) 19.175 (6)
Note.—Data are net health benefi ts. Numbers in parentheses are rank, which was assigned from most effi cient (score, 1) to least effi cient (score, 6) given the indicated opportunity cost of health care 
expenditures.
* COLO = colonoscopy at 10-year intervals, CTC5 = CT colonography with 5-mm referral threshold at 5-year intervals, CTC10 = CT colonography with 5-mm referral threshold at 10-year intervals, 
FIT+FS = annual FIT plus fl exible sigmoidoscopy at 5-year intervals, FOBT+FS = annual unrehydrated FOBT plus fl exible sigmoidoscopy at 5-year intervals.
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 The CISNET models found that for 
an asymptomatic, average-risk cohort 
of 50-year-old subjects in the United 
States, CT colonography screening ev-
ery 5 or 10 years is more costly and less 
effective than guideline-concordant non-
CT colonography screening approaches 
under both perfect and less than ideal 
adherence, given model assumptions and 
current cost estimates. The CISNET 
models also found that although CT 
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ommended screening, it may be cost-
effective compared with no screening. 
The models also found that 5-year screen-
ing intervals are likely to be net benefi cial 
compared with 10-year intervals. That 
three independent models reached sim-
ilar conclusions adds credibility to our 
fi ndings. 
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